Needham Maintains Buy on Cytokinetics, Lowers Price Target to $58
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $60 to $58.
Analyst Ratings for Cytokinetics
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Truist Securities Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $60
Truist Securities analyst Srikripa Devarakonda initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $60.
UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $66
UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and lowers the price target from $80 to $66.
Goldman Sachs Maintains Buy on Cytokinetics, Lowers Price Target to $47
Goldman Sachs analyst Madhu Kumar maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $55 to $47.
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
FDA Adcomm Gives Thumbs Down To Cytokinetics’ Heart Failure Candidate
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics Incorporated’s (NASDAQ:CYTK) heart failure drug, omecamtiv mecarbil.…
Cytokinetics Announced Stock Trading Halted Today for FDA Panel to Review NDA for Omecamtiv Mecarbil
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nasdaq has halted the trading of the Company's common stock. The U.S.